ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Integrated skin-lesion transcriptomics prioritises biomarker-candidate host-response genes with pharmacological annotation in leprosy type 1 reaction.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 reaction (T1R) is an inflammatory complication of leprosy that can affect skin and peripheral nerves, but the lesion-level host-response genes distinguishing reactional from non-reactional borderline disease remain incompletely defined. This study analysed the GSE74481 skin-lesion transcriptomic dataset to compare T1R_R1 lesions with borderline non-reaction lesions and used an evidence-guided prioritisation approach to organise the lesion-derived expression signal. Differential expression analysis of 44 skin-lesion samples identified 3630 differentially expressed genes, including 1979 upregulated and 1651 downregulated genes in T1R_R1 lesions. T1R_R1-upregulated genes were enriched for immune-cell recruitment, interleukin-related signalling, neutrophil activation and extracellular matrix organisation, whereas borderline non-reaction lesions showed stronger epithelial and skin-development programmes. Co-expression and candidate-prioritisation analyses identified 23 final Tier 1 candidates within this broader inflammatory and tissue-remodelling response, including genes linked to myeloid activity, oxidative response, cytokine-interferon-related signalling, endothelial interaction and matrix remodelling. The final candidate signature showed within-cohort separation of T1R_R1 from borderline non-reaction lesions, with an apparent internal AUC of 0.955. Most detected skin-derived candidates also showed the same direction of change in the blood-based GSE269151 T1R contrast, supporting partial cross-tissue direction-of-effect concordance. DGIdb and ChEMBL analyses linked representative candidates, including JAK2, ICAM1 and TNF, to existing drug-gene or target-level annotations, providing pharmacological context for hypothesis generation. These findings define a discovery-stage lesion-derived T1R host-response profile and prioritise candidate genes for future validation in independent lesion cohorts and experimental systems.
Indexed as
Identifiers
42698029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.